Abstract
Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.
| Original language | English |
|---|---|
| Pages (from-to) | 256-258 |
| Number of pages | 3 |
| Journal | Experimental and Clinical Transplantation |
| Volume | 13 |
| DOIs | |
| Publication status | Published - 2015 Jan 1 |
Fingerprint
Keywords
- End-stage renal disease
- Infectious diseases
- Lamivudine
ASJC Scopus subject areas
- Transplantation
Cite this
Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country. / Jun, Heungman; Kim, Myung-Gyu; Park, Kwan Tae; Jung, Cheol Woong.
In: Experimental and Clinical Transplantation, Vol. 13, 01.01.2015, p. 256-258.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country
AU - Jun, Heungman
AU - Kim, Myung-Gyu
AU - Park, Kwan Tae
AU - Jung, Cheol Woong
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.
AB - Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.
KW - End-stage renal disease
KW - Infectious diseases
KW - Lamivudine
UR - http://www.scopus.com/inward/record.url?scp=84939813634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939813634&partnerID=8YFLogxK
U2 - 10.6002/ect.mesot2014.P60
DO - 10.6002/ect.mesot2014.P60
M3 - Article
C2 - 25894166
AN - SCOPUS:84939813634
VL - 13
SP - 256
EP - 258
JO - Experimental and Clinical Transplantation
JF - Experimental and Clinical Transplantation
SN - 1304-0855
ER -